FH and renal cell carcinoma: More recently, there was an emergence of a novel therapy for FH‐deficient RCC that includes bevacizumab, an anti‐VEGF monoclonal antibody, and erlotinib, an anti‐EGFR tyrosine kinase inhibitor.155, 156